Browse

Joshua Pinto, Ph.D., has been appointed chief executive officer of Neumora Therapeutics, a clinical-stage biotech with obesity and neuro assets.

Merck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be…